The Race for the COVID Vaccine has Reemphasized the Need for a Robust Cold Supply Chain

 

The wait for the COVID vaccine is coming to an end as multiple pharmaceutical companies have announced effective treatments in recent weeks. The next challenge is the massive distribution of vaccines that require cold storage at extreme temperatures. 

Daniel Litwin, Guest Host and the Voice of B2B was joined by Joseph Battoe to discuss the issue of transporting vaccines that require cold storage on a global scale. 

Battoe is the CEO of Varcode, a technology company that enables pharmaceutical companies to verify product safety throughout the supply chain.

Designing a robust, effective, and efficient supply chain for pharmaceuticals has been an evergreen challenge. Nearly 80% of pharmaceutical products require temperature control.  Products being wasted during transportation is an ongoing issue with billions of dollars lost each year.

This ongoing issue is even more important with the distribution of the COVID-19 vaccine.

“The fastest to develop, but the hardest to deploy,” said Battoe when asked if there is added pressure for handling the logistics of transporting the COVID-19 vaccine.  Some of the COVID vaccines require extreme cold temperatures during transportation: minus 70-80 degrees celsius in some cases.  “It’s unprecedented speed.  It’s unprecedented scale.”

Battoe sees the greater challenge being the delivery of lower volumes of vaccines to more remote or rural locations.  That’s where Varcode excels in assisting with the logistics on the smaller scale needs where the benefits of bulk orders cannot be realized.

It will take a multitude of products and services to ensure the vaccine is distributed successfully around the world.  Hundreds of companies, including Varcode, will be working together to safely deliver COVID vaccine globally.

Catch up on previous episodes of I Don’t Care with Kevin Stevenson!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More